Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Non-Small Cell Lung Cancer”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Very early researchNot Yet RecruitingNCT07671092
What this trial is testing

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Who this might be right for
Metastatic Urothelial CarcinomaBreast CancerTNBC - Triple-Negative Breast Cancer+2 more
RayzeBio, Inc. 40
Early research (Phase 1)Active Not RecruitingNCT04042701
What this trial is testing

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Who this might be right for
Breast CancerNon-small Cell Lung Carcinoma
Daiichi Sankyo 115
Not applicableEnded earlyNCT04106167
What this trial is testing

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Who this might be right for
Advanced Solid TumorLymphomaGastric Cancer+15 more
Fate Therapeutics 20
Not applicableLooking for participantsNCT07610616
What this trial is testing

Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids

Who this might be right for
HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer
Guangzhou Institute of Respiratory Disease 10
Testing effectiveness (Phase 2)Looking for participantsNCT04144569
What this trial is testing

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

Who this might be right for
HER2 Insertion Mutation Positive Advanced NSCLC
Yongchang Zhang 30
Testing effectiveness (Phase 2)UnknownNCT06519110
What this trial is testing

Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations

Who this might be right for
Advanced Solid Tumor
Convalife (Shanghai) Co., Ltd. 60
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)Ended earlyNCT01217411
What this trial is testing

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Who this might be right for
Adult Solid NeoplasmExtensive Stage Lung Small Cell CarcinomaHER2/Neu Negative+10 more
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Early research (Phase 1)Study completedNCT00228358
What this trial is testing

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerRecurrent Non-small Cell Lung Cancer+6 more
University of Washington 8
Early research (Phase 1)Study completedNCT05159518
What this trial is testing

PRT2527 in Participants With Advanced Solid Tumors

Who this might be right for
SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more
Prelude Therapeutics Incorporated 30
Early research (Phase 1)Study completedNCT03219268
What this trial is testing

MGD013 in Patients With Unresectable or Metastatic Neoplasms

Who this might be right for
Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more
MacroGenics 277
Testing effectiveness (Phase 2)Ended earlyNCT03784599
What this trial is testing

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
The Netherlands Cancer Institute 28
Early research (Phase 1)Looking for participantsNCT06625775
What this trial is testing

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 392
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Testing effectiveness (Phase 2)Study completedNCT02289833
What this trial is testing

Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 49
Early research (Phase 1)Study completedNCT03319459
What this trial is testing

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Who this might be right for
HER2 Positive Gastric CancerColorectal CancerHead and Neck Squamous Cell Carcinoma+8 more
Fate Therapeutics 44
Testing effectiveness (Phase 2)Ended earlyNCT04504916
What this trial is testing

Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Who this might be right for
Triple-negative Breast CancerNon-squamous Non-small-cell Lung CancerNSCLC+12 more
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 102
Post-approval studies (Phase 4)Not Yet RecruitingNCT07768358
What this trial is testing

Tucatinib Continuation Study

Who this might be right for
HER2-positive Breast CancerCervical CancerBiliary Tract Neoplasms+4 more
Pfizer 175
Next Page